Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 11929

Allows for more easily building tiny machines, biomedical sensors, optical computers, solar panels, and other devices — no complex clean room required; portable version planned.

Illustration of the bubble-pen pattern-writing process using an optically controlled microbubble on a plasmonic substrate. The small blue spheres are colloidal nanoparticles. (credit: Linhan Lin et al./Nano Letters)

Researchers in the Cockrell School of Engineering at The University of Texas at Austin have created “bubble-pen lithography” — a device and technique to quickly, gently, and precisely use microbubbles to “write” using gold, silicon and other nanoparticles between 1 and 100 nanometers in size as “ink” on a surface.

Continue reading “‘Bubble pen’ can precisely write patterns with nanoparticles as small as 1 nanometer” | >

Excellent news; Intellia to continue their focus of leveraging the CRISPR/Cas9 across a variety of immune cells, such as natural killer cells and T-cells. From my own experiences with T-cells and other blood disorders; this is a big deal and one that I personally excited to see what potential cures and improvements come about.

CAMBRIDGE, Mass.–()–Intellia Therapeutics, a leading gene-editing company, has launched a new division, eXtellia Therapeutics, with the intent of focusing resources and research on ex vivo applications of the novel technology, CRISPR/Cas9. As in vivo and ex vivo programs require different competencies in research, manufacturing and commercialization, eXtellia Therapeutics is being launched to accelerate Intellia’s efforts in areas of significant unmet medical need – immuno-oncology, autoimmune and inflammatory diseases – using an ex vivo approach. Intellia will continue its in vivo programs and strategy through a dedicated scientific team.

“We are excited to announce the establishment of eXtellia, increasing our footprint in ex vivo gene editing for oncology and autoimmune diseases,” said Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, Intellia Therapeutics. “eXtellia enables us to bring together the required capabilities needed to take the CRISPR/Cas9 technology beyond Intellia’s emerging in vivo, HSC and CAR-T efforts. We believe eXtellia further positions us to maximize the CRISPR/ Cas9 opportunity to address severe unmet medical needs for patients.”

Continue reading “Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/Cas9” | >

I truly love teleporting.

Teleporting the memories of an organism is possible, say scientists working on making the science-fiction phenomena come to life. They have come up with a theory that uses “quantum superposition” to place a microorganism in two places at once.

The Chinese physicists have drawn up a plan to use electromechanical oscillators and superconducting circuits to “teleport” the microbe. Its quantum state will be moved elsewhere, resulting in a big first step toward human teleportation.

Tongcang Li, co-author of the study from Purdue University, said: “We propose a straightforward method to put a microorganism in two places at the same time, and provide a scheme to teleport the quantum state of a microorganism.”

Continue reading “Teleportation of bacteria’s memories made possible” | >

Friends,

When Singularity Hypotheses was published, the technological singularity was (barely) a fringe academic topic. Three years later, and the singularity is in the headlines of every magazine and tabloid.

Yet the subject became even more controversial, with some very polarizing views confusing the public.

We’ve decided to help policy makers understand the technological singularity and publish this report. It is intended to clarify the debate, refute common misconceptions, and highlight the open questions.

Please comment below with your views!

Continue reading “The Singularity Controversy, Part I: Lessons Learned and Open Questions: Conclusions from the Battle on the Legitimacy of the Debate” | >

This is excellent news for Epilepsy.

Epilepsy, a disorder in which nerve cell activity in the brain is disturbed, causing seizures, is the fourth most common neurological problem, following only migraine, stroke and Alzheimer’s. There is no cure for epilepsy, but there are a variety of treatment options. The disease is estimated to affect 2.2 million people in the U.S., with 150,000 people developing the condition each year.

Personalized medicine Scientists at AES discussed how new technologies, such as gene editing using CRISPR-Cas9, and next-generation sequencing, are empowering them to take a new crack at the human genome and find new ways to diagnose and treat epilepsy.

“Recent advances in DNA sequencing and genomic technologies has facilitated a flood of discoveries in identifying genetic causes of epilepsy. Where we’ve been most successful is in the epileptic encephalopathies (EE),” lead author of one of the studies presented, Candace Myers, a senior at the University of Washington, said in a press conference.

Read more

Gerd predicts that machines will have the same power of a human brain by 2025.

By the year 2025, machines will have the same power as the human brain and in 2051 they will have the power of the entire global population. Does is sound far-fetched? It is certainly a grand claim, but who better to make these kinds of observations than Gerd Leonhard, Futurist, Keynote Speaker, Author and CEO of The Futures Agency.

This was one of the many observations Mr Leonhard spoke to The Malta Independent about ahead of his Keynote Address for The Economist at their ‘The World in 2016 Gala Dinner’ tonight at the Hilton, St Julian’s; where every year they invite experts and innovators from all over the world to share their ‘predictions’ for the coming year.

Mr Gerd Leonhard is a futurist, which means that his main role is to observe and deduce plausible scenarios for the future of an industry, an organization or even a country. He does not call his observations ‘predictions’, but ‘foresight’ which, according to Mr Leonhard, everyone can do but while everyone tends to look at “95% today, while [he looks] at 95% tomorrow.”

Read more